Optimizing Patient Outcomes in R/R DLBCL: Bridging Knowledge Gaps for Oncology Pharmacists in the Era of Novel Immunotherapies

Program Description

The management of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) has become increasingly complex due to the rapid evolution of novel immunotherapies. However, the pace of change has led to challenges in staying informed of evidence-based treatment recommendations, sequencing of therapies, and managing adverse effects. Oncology pharmacists are crucial in guiding clinicians on therapy selection and tailoring treatment plans to individual patient needs, but many have limited experience with these novel immunotherapies, making it difficult for them to incorporate patient- and disease-specific factors into treatment decisions. The session will dissect treatment algorithms for both frontline and relapsed/refractory DLBCL, emphasizing considerations for therapy selection, including patient-specific factors, prior treatments, and adverse effect profiles.

Target Audience: Oncology Pharmacist

Type of Activity: Application
Release date: September 30, 2025
Expiration date: September 30, 2026
Learner level: Foundational, Intermediate
Time to complete activity: 1.25 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

1. Explore the role of novel immunotherapies in the management of relapsed/refractory diffuse large B-cell lymphoma (DLBCL), including their mechanisms of action, clinical efficacy, and safety considerations
2. Evaluate patient- and disease-specific factors that influence treatment decisions, including eligibility for novel immunotherapies and considerations for tailoring therapy to individual needs
3. Examine pharmacist-led approaches for preventing, monitoring, and managing adverse effects related to novel immunotherapies.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.25 contact hours (0.125 CEU) under the ACPE universal activity number 0290-0000-25-311-H01-P. The activity is available for CE credit through September 30, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Faculty

James A. Davis, PharmD, BCOP

Consultant: Bristol Myers Squibb, GSK, Janssen

Speakers Bureau: Janssen

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Amy L. Morris, PharmD, BCOP; Daphne Davis, PharmD, BCOP; Victoria Chirdo; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with ineligible companies to disclose.

Pharmacy Times® Editorial Staff— Aislinn Antrim

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms